Live Breaking News & Updates on Ose Immunotherapeutics Stock Exchange

Stay updated with breaking news from Ose immunotherapeutics stock exchange. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Four Poster Presentations at 2022 ASCO Annual Meeting

NSCLC Atalante-1 Phase 3 Trial Beyond Checkpoint Inhibitor Neoepitope Specific Immunotherapy Tedopi® Shows Significant Patient-Reported Outcomes Versus ChemotherapyPositive Interim Results in. | June 7, 2022 ....

France General , Regina Elena , Dominique Costantini , Federico Cappuzzo , Gustave Roussy , Alexandra Leary , Anthony Turpin , Benjamin Besse , Lille University Hospital , Nantes University Hospital , Oncology At Cancer Institute , Boehringer Ingelheim , Gustave Roussy Institute , Veloxis Pharmaceuticals Inc , Fort Foundation Fondazione Ricerca Traslazionale , Interim Results , Pancreatic Cancer , Maintenance Strategy , Fondazione Ricerca Traslazionale , Roussy Institute , Patient Reported Outcomes , Chief Executive Officer , University Hospital , Open Label , Randomized Trial Evaluating Efficacy , After First Line ,

OSE Immunotherapeutics Presentation at H.C. Wainwright Global Life Sciences Conference

NANTES, France, Feb. 23, 2021 (GLOBE NEWSWIRE)
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of the Company’s business at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-11, 2021.
The presentation will be available for on-demand listening beginning March 9 at 7:00 am (EST) / 1:00 pm (CET) and archived for 90 days.
Webcasting link:
ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile: ....

Alexis Peyroles , Hc Wainwright Global Life Sciences Conference , Boehringer Ingelheim , Chief Executive Officer , Global Life Sciences Conference , Non Small Cell Lung Cancer , Ose Immunotherapeutics Stock Exchange , Press Release , At Ose Fr0012127173 , ஹ்ஸீ வேந்‌ரைட் உலகளாவிய வாழ்க்கை அறிவியல் மாநாடு , போஹெரிங்கர் இஂகல்‌ஹைம் , தலைமை நிர்வாகி அதிகாரி , உலகளாவிய வாழ்க்கை அறிவியல் மாநாடு , அல்லாத சிறிய செல் நுரையீரல் புற்றுநோய் , ப்ரெஸ் வெளியீடு ,